Assembly Biosciences vs Kura Oncology
Assembly Biosciences and Kura Oncology are similar in size: $72.3m and $67.5m of revenue in their latest fiscal years. Assembly Biosciences grew faster (153.5% against 25.2%). Assembly Biosciences kept more of each dollar of sales as profit: a net margin of -8.5% against -412.9%. Assembly Biosciences carries less debt relative to equity (0.0% against 5.6%).
| Latest fiscal year | Assembly BiosciencesASMB, 2025 | Kura OncologyKURA, 2025 |
|---|---|---|
| Revenue | $72.3m | $67.5m |
| Revenue growth | 153.5% | 25.2% |
| Net income | −$6.1m | −$279m |
| Operating margin | -16.8% | -449.9% |
| Net margin | -8.5% | -412.9% |
| Return on equity | -5.1% | -94.8% |
| Free cash flow | −$41.2m | −$70.7m |
| Cash | $58.5m | $149m |
| Total debt | $0 | $9.7m |
| Debt to equity | 0.0% | 5.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 260 |
| Market value | $392m | $879m |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | — |
| Insider trades, 12 months | 0 buys, 5 sales | 2 buys, 39 sales |